Cargando…

Clinical Course of Bacillus Calmette-Guerin Lymphadenitis

Bacillus Calmette-Guerin (BCG) vaccination can cause lymphadenitis. The purpose of the current study was to describe patient characteristics and clinical courses of lymphadenitis associated with BCG vaccination. A total of 171 patients who visited a tertiary hospital with a diagnosis of BCG-associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Dayoung, Han, Ji-Won, Youn, Joongkee, Yang, Hee-Beom, Oh, Chaeyoun, Yun, Ki-Wook, Kim, Hyun-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140195/
https://www.ncbi.nlm.nih.gov/pubmed/35626787
http://dx.doi.org/10.3390/children9050610
_version_ 1784715039516655616
author Ko, Dayoung
Han, Ji-Won
Youn, Joongkee
Yang, Hee-Beom
Oh, Chaeyoun
Yun, Ki-Wook
Kim, Hyun-Young
author_facet Ko, Dayoung
Han, Ji-Won
Youn, Joongkee
Yang, Hee-Beom
Oh, Chaeyoun
Yun, Ki-Wook
Kim, Hyun-Young
author_sort Ko, Dayoung
collection PubMed
description Bacillus Calmette-Guerin (BCG) vaccination can cause lymphadenitis. The purpose of the current study was to describe patient characteristics and clinical courses of lymphadenitis associated with BCG vaccination. A total of 171 patients who visited a tertiary hospital with a diagnosis of BCG-associated lymphadenitis between January 2012 and June 2017 were included. The diagnostic criteria were a history of BCG vaccination on the symptomatic side, absence of tenderness and raised temperature over the swelling, absence of fever and constitutional symptoms, and isolated axillary (or supraclavicular/cervical) lymph node (LN) enlargement. Treatment strategies included observation, antibiotics, incision and drainage or needle aspiration (I&D/NA), and surgical excision. The median follow-up period was 40 days (range 1–1245 days). The median age at the first visit was 5.5 months (range 0.9–83.7 months). The most common location was the axilla (81.3%). The respective numbers of patients managed via observation, I&D/NA, antibiotics, and surgical excision were 99, 47, 5, and 20. LNs were significantly more enlarged in the I&D/NA group than in the antibiotics group and the observation group. The respective times taken for residual lesions to reduce to < 20% were approximately 3 months, 4 months, and 5 months in the antibiotics, observation, and I&D/NA groups. The surgery group had significantly fewer residual lesions than the observation group at the last visit, but there was no significant difference in current residual lesions between the groups. LNs were significantly larger in the I&D/NA group. The surgery group exhibited the least residual lesions at the last visit, but there was no significant difference in current status.
format Online
Article
Text
id pubmed-9140195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91401952022-05-28 Clinical Course of Bacillus Calmette-Guerin Lymphadenitis Ko, Dayoung Han, Ji-Won Youn, Joongkee Yang, Hee-Beom Oh, Chaeyoun Yun, Ki-Wook Kim, Hyun-Young Children (Basel) Article Bacillus Calmette-Guerin (BCG) vaccination can cause lymphadenitis. The purpose of the current study was to describe patient characteristics and clinical courses of lymphadenitis associated with BCG vaccination. A total of 171 patients who visited a tertiary hospital with a diagnosis of BCG-associated lymphadenitis between January 2012 and June 2017 were included. The diagnostic criteria were a history of BCG vaccination on the symptomatic side, absence of tenderness and raised temperature over the swelling, absence of fever and constitutional symptoms, and isolated axillary (or supraclavicular/cervical) lymph node (LN) enlargement. Treatment strategies included observation, antibiotics, incision and drainage or needle aspiration (I&D/NA), and surgical excision. The median follow-up period was 40 days (range 1–1245 days). The median age at the first visit was 5.5 months (range 0.9–83.7 months). The most common location was the axilla (81.3%). The respective numbers of patients managed via observation, I&D/NA, antibiotics, and surgical excision were 99, 47, 5, and 20. LNs were significantly more enlarged in the I&D/NA group than in the antibiotics group and the observation group. The respective times taken for residual lesions to reduce to < 20% were approximately 3 months, 4 months, and 5 months in the antibiotics, observation, and I&D/NA groups. The surgery group had significantly fewer residual lesions than the observation group at the last visit, but there was no significant difference in current residual lesions between the groups. LNs were significantly larger in the I&D/NA group. The surgery group exhibited the least residual lesions at the last visit, but there was no significant difference in current status. MDPI 2022-04-25 /pmc/articles/PMC9140195/ /pubmed/35626787 http://dx.doi.org/10.3390/children9050610 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ko, Dayoung
Han, Ji-Won
Youn, Joongkee
Yang, Hee-Beom
Oh, Chaeyoun
Yun, Ki-Wook
Kim, Hyun-Young
Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
title Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
title_full Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
title_fullStr Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
title_full_unstemmed Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
title_short Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
title_sort clinical course of bacillus calmette-guerin lymphadenitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140195/
https://www.ncbi.nlm.nih.gov/pubmed/35626787
http://dx.doi.org/10.3390/children9050610
work_keys_str_mv AT kodayoung clinicalcourseofbacilluscalmetteguerinlymphadenitis
AT hanjiwon clinicalcourseofbacilluscalmetteguerinlymphadenitis
AT younjoongkee clinicalcourseofbacilluscalmetteguerinlymphadenitis
AT yangheebeom clinicalcourseofbacilluscalmetteguerinlymphadenitis
AT ohchaeyoun clinicalcourseofbacilluscalmetteguerinlymphadenitis
AT yunkiwook clinicalcourseofbacilluscalmetteguerinlymphadenitis
AT kimhyunyoung clinicalcourseofbacilluscalmetteguerinlymphadenitis